Estimating shared polygenicity identifies novel druggable genes for Alzheimer's disease

The set of AD exclusive genes which are viable druggable candidates is likely very small. This highlights the utility of evaluating the set of repurposable candidates, which we show may be significantly larger. Together, our work highlights the power of our method to identify putatively safer and efficacious drug targets for AD and other AD-related dementia if broadly applied.